Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine, Venetoclax and Blinatumomab Maintenance in Ph-Negative B-ALL
NCT06393985Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, venetoclax, blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by First Affiliated Hospital of Soochow University. Started Apr 2024; status: recruiting.
02
Drugs
decitabinevenetoclaxblinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06393985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393985.